Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOHARM: Hydroxyurea in African Region With Malaria
NCT01976416Phase 3Completed
- Sponsor
- Indiana University
- Start
- Sep 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell anemia (SCA) comparing Hydroxyurea with Placebo (2 arms). Primary endpoint: Incidence of Malaria Episodes at 12 months. Started Sep 2014; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT01976416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01976416.